EnteroBiotix Completes Recruitment for Phase 2 Study EBX-102-02
EnteroBiotix, a forward-thinking clinical-stage biotechnology firm, has reached a significant milestone in its mission to tackle irritable bowel syndrome (IBS) with innovative therapies. The company has successfully completed the recruitment phase of its Phase 2 TrIuMPH trial, targeting the efficacy of their leading treatment candidate, EBX-102-02. This trial focuses on addressing the pressing needs of patients suffering from IBS, which affects a substantial segment of the population.
Study Overview and Participant Recruitment
In total, 122 patients suffering from moderate to severe IBS were enrolled in the TrIuMPH trial. Of these, 62 participants were identified as having constipation-predominant IBS (IBS-C), while the remaining 60 were diagnosed with diarrhoea-predominant IBS (IBS-D). The successful completion of participant recruitment was achieved ahead of schedule, highlighting the strong interest from patients and the efficiency of the clinical team.
Trial Design and Objectives
The Phase 2 TrIuMPH trial is designed as a randomized, double-blind, placebo-controlled study. Patients were randomized in a 2:1 ratio to receive either the investigational drug EBX-102-02 or a placebo administered over two time points spaced one week apart. The study objectives are twofold: primarily, to assess the safety and tolerability of EBX-102-02 in patients with severe IBS; and secondarily, to evaluate its efficacy, alongside observing changes in gut microbiome composition, function, and associated biomarkers.
CEO Insights on Trial Progress
Dr. James McIlroy, CEO of EnteroBiotix, expressed gratitude towards both trial participants and investigators for their vital contributions to reaching this recruitment milestone ahead of schedule. He noted, "The swift enrolment reflects patients’ intense interest and the dire need for innovative IBS treatments that target microbiome imbalances. We are excited about the opportunity to present topline data early in the upcoming year."
Company Background and Its Innovative Approach
EnteroBiotix is at the forefront of developing cutting-edge therapeutics aimed at treating gastrointestinal and hepatic diseases. Their approach involves utilizing dynamic ecosystems of microorganisms regulated by proprietary technology, promoting improved gut health and restoring microbiome balance. The completion of the Phase 2 study on IBS is just one component of a broader strategy, which also includes a Phase 2a study in collaboration with Imperial College aimed at patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Recent Developments in Clinical Research
Recently, EnteroBiotix announced promising results from a Phase 1b clinical study focused on EBX-102, which targets patients with liver cirrhosis. The study demonstrated significant proof-of-principle across various microbiome assessments and inflammatory biomarkers, validating the company's ongoing research and commitment towards pioneering microbial therapies for liver diseases.
Additional Information About EBX-102-02
EBX-102-02 promises to deliver an innovative treatment form by utilizing a full-spectrum drug candidate encapsulated in a user-friendly capsule format. This candidate is designed to maintain stability at room temperature, ensuring ease of use for patients. Its formulation contains a diverse array of microorganisms aimed at restoring gut health and supporting the body’s microbiome.
Understanding Irritable Bowel Syndrome (IBS)
IBS is a chronic and relapsing functional gastrointestinal disorder characterized by various symptoms including chronic abdominal pain, cramping, bloating, and irregular bowel habits. It is estimated that a staggering 1 in 8 individuals may experience symptoms associated with IBS. This disorder creates considerable indirect medical costs, with estimates reaching upwards of $20 billion annually. Despite its prevalence, effective treatment options remain critically needed.
The Functional Gut Clinic Partnership
The collaboration with the Functional Gut Clinic enhances EnteroBiotix’s capabilities to conduct advanced gastrointestinal physiology testing. As a leading independent provider in its field, FGC plays a pivotal role in advancing experimental and clinical trials related to digestive health. Their extensive experience enriches the study's integrity and precision, ultimately aiming to develop improved diagnostic and therapeutic options for patients.
Frequently Asked Questions
What is the TrIuMPH trial?
The TrIuMPH trial is a Phase 2 study aimed at evaluating the safety and tolerability of EBX-102-02 in patients suffering from IBS.
How many patients were recruited for the study?
A total of 122 patients with moderate to severe IBS were recruited for the Phase 2 TrIuMPH trial.
What are the primary objectives of the trial?
The primary objective is to assess the safety and tolerability of the treatment, while secondary objectives include evaluating efficacy and changes in gut microbiome composition.
Who is leading the research for EnteroBiotix?
Dr. James McIlroy, the CEO of EnteroBiotix, is at the helm of the company's research efforts and commented on their recruitment success.
What potential impact does IBX-102-02 have on IBS patients?
EBX-102-02 aims to offer a novel treatment option that addresses gut microbiome imbalances, which may provide relief for IBS symptoms.
